Instil Bio
95 hedge funds and large institutions have $577M invested in Instil Bio in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 14 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 24
5% more capital invested
Capital invested by funds: $551M → $577M (+$26.1M)
0.01% less ownership
Funds ownership: 4.61% → 4.6% (-0.01%)
3% less funds holding
Funds holding: 98 → 95 (-3)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.23M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$2.6M |
| 3 |
BlackRock
New York
|
+$2.43M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.3M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$10.8M |
| 2 |
Renaissance Technologies
New York
|
-$1.64M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$1.48M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.14M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$933K |
TIL Hedge Fund Activity: Q3 2022 in Review
95 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q3 2022, worth a combined $577M — up 4.7% from $551M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TIL and 11 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 34 added.
The largest buyer was Vanguard Group, adding an estimated $5.23M. The largest seller was VR Adviser, cutting an estimated $10.8M.
- 95 institutional investors held Instil Bio (TIL) as of Q3 2022, down from 98 in Q2 2022.
- Funds reported $577M of Instil Bio stock for Q3 2022, up 4.7% quarter-over-quarter.
- 11 funds opened new Instil Bio positions in Q3 2022 and 14 closed out, a net change of -3 holders.
- The largest Instil Bio buyer in Q3 2022 was Vanguard Group, an estimated $5.23M added.
- The largest Instil Bio seller in Q3 2022 was VR Adviser, an estimated $10.8M sold.
Based on aggregated 13F filings for Q3 2022.